Pantoprazole may improve beta cell function and diabetes mellitus

Basit Öğe Kaydı
dc.contributor.authorInci, F.
dc.contributor.authorAtmaca, M.
dc.contributor.authorOzturk, M.
dc.contributor.authorYildiz, S.
dc.contributor.authorKoceroglu, R.
dc.contributor.authorSekeroglu, R.
dc.contributor.authorIpekci, S. H.
dc.date.accessioned2020-03-26T18:51:58Z
dc.date.available2020-03-26T18:51:58Z
dc.date.issued2014
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground Proton pump inhibitors induce hypergastrinemia by suppressing gastric acidity. Gastrin has incretin-like stimulating actions on beta cells. Proton pump inhibitors have been shown to decrease glycosylated hemoglobin. Aim We aimed to observe changes in beta cell function in diabetic and non-diabetic subjects given pantoprazole for an acid-related ailment. Methods Seventy-nine male patients (38 non-diabetic and 41 type-2 diabetic receiving only metformin therapy) were followed for 12 weeks after pantoprazole 40 mg/day was given. Fasting plasma glucose, HbA1c, fasting insulin, Pancreatic B cell function (HOMA-B), proinsulin and c-peptide levels were measured before and after the treatment. Results In non-diabetic patients (n = 38), FPG decreased, whereas c-peptide, log-HOMA-B, increased significantly (p = 0.002, p = 0.03, p = 0.042, respectively) after 12 weeks of pantoprazole administration. In type 2 diabetic patients, FPG, HbA1c and weight decreased, whereas log-HOMA-B, c-peptide and log-proinsulin levels increased significantly after pantoprazole treatment (p = 0.003, p = 0.007, p < 0.001; p < 0.001; p = 0.017, p = 0.05, respectively). After pantoprazole treatment, pancreatic B-cell function was correlated with c-peptide and insulin and inversely with FBG and HbA1c levels in the whole group (r = 0.37, p = 0.001; r = 0.60, p < 0.001, r = -0.29, p = 0.011 and r = -0.28, p = 0.013, respectively). After pantoprazole treatment, HbA1c was correlated with FBG (r = 0.75, p < 0.001) and inversely with only log-HOMA-B level (r = -0.28, p = 0.013). Conclusions Pantoprazole administration seems to correlate with increased beta cell function. Pantoprazole administration improves HbA1c, HOMA-B, c-peptide and proinsulin levels. Since beta cell loss plays a significant role in the pathogenesis of type 2 diabetes, PPI-based therapies may be useful in the treatment of diabetes.en_US
dc.identifier.doi10.1007/s40618-013-0040-yen_US
dc.identifier.endpage454en_US
dc.identifier.issn0391-4097en_US
dc.identifier.issn1720-8386en_US
dc.identifier.issue5en_US
dc.identifier.pmid24682913en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage449en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s40618-013-0040-y
dc.identifier.urihttps://hdl.handle.net/20.500.12395/31055
dc.identifier.volume37en_US
dc.identifier.wosWOS:000335152700005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofJOURNAL OF ENDOCRINOLOGICAL INVESTIGATIONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectDiabetes mellitusen_US
dc.subjectPantoprazoleen_US
dc.subjectHOMA-Ben_US
dc.subjectC-peptideen_US
dc.subjectInsulinen_US
dc.subjectProinsulinen_US
dc.titlePantoprazole may improve beta cell function and diabetes mellitusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu